Sign up to access all valuation multiples
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
2021
1.8K+
LTM Revenue $451M
LTM EBITDA $66.5M
$700M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of September 2025, ZimVie reported last 12-month revenue of $451M and EBITDA of $66.5M.
In the same period, ZimVie generated $296M in LTM gross profit and $14.0M in net income.
See ZimVie valuation multiples based on analyst estimatesIn the most recent fiscal year, ZimVie reported revenue of $450M and EBITDA of $29.6M.
ZimVie expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ZimVie valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $451M | XXX | $450M | XXX | XXX | XXX |
| Gross Profit | $296M | XXX | $287M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $66.5M | XXX | $29.6M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 7% | XXX | XXX | XXX |
| EBIT | $37.2M | XXX | -$2.1M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 0% | XXX | XXX | XXX |
| Net Profit | $14.0M | XXX | -$25.8M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | -6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $145M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ZimVie has current market cap of $536M, and EV of $700M.
As of October 17, 2025, ZimVie's stock price is $19.
See ZimVie trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $700M | $536M | XXX | XXX | XXX | XXX | $0.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialZimVie's trades at 1.6x EV/Revenue multiple, and 23.6x EV/EBITDA.
See valuation multiples for ZimVie and 15K+ public compsAs of October 17, 2025, ZimVie has market cap of $536M and EV of $700M.
Equity research analysts estimate ZimVie's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ZimVie has a P/E ratio of 38.4x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $536M | XXX | $536M | XXX | XXX | XXX |
| EV (current) | $700M | XXX | $700M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 10.5x | XXX | 23.6x | XXX | XXX | XXX |
| EV/EBIT | 18.8x | XXX | -333.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 38.4x | XXX | -20.7x | XXX | XXX | XXX |
| EV/FCF | 54.7x | XXX | 93.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZimVie's last 12 month revenue growth is 1%
ZimVie's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
ZimVie's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ZimVie's rule of X is 17% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ZimVie and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | -13% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 8% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ZimVie acquired XXX companies to date.
Last acquisition by ZimVie was XXXXXXXX, XXXXX XXXXX XXXXXX . ZimVie acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was ZimVie founded? | ZimVie was founded in 2021. |
| Where is ZimVie headquartered? | ZimVie is headquartered in United States of America. |
| How many employees does ZimVie have? | As of today, ZimVie has 1.8K+ employees. |
| Who is the CEO of ZimVie? | ZimVie's CEO is Mr. Vafa Jamali. |
| Is ZimVie publicy listed? | Yes, ZimVie is a public company listed on NAS. |
| What is the stock symbol of ZimVie? | ZimVie trades under ZIMV ticker. |
| When did ZimVie go public? | ZimVie went public in 2022. |
| Who are competitors of ZimVie? | Similar companies to ZimVie include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of ZimVie? | ZimVie's current market cap is $536M |
| What is the current revenue of ZimVie? | ZimVie's last 12 months revenue is $451M. |
| What is the current revenue growth of ZimVie? | ZimVie revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of ZimVie? | Current revenue multiple of ZimVie is 1.6x. |
| Is ZimVie profitable? | Yes, ZimVie is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ZimVie? | ZimVie's last 12 months EBITDA is $66.5M. |
| What is ZimVie's EBITDA margin? | ZimVie's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of ZimVie? | Current EBITDA multiple of ZimVie is 10.5x. |
| What is the current FCF of ZimVie? | ZimVie's last 12 months FCF is $12.8M. |
| What is ZimVie's FCF margin? | ZimVie's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of ZimVie? | Current FCF multiple of ZimVie is 54.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
